Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated May 29, 2018 (8 years ago)

Nystatin Oral Suspension

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Resuspension problems: Out of specification for appearance and resuspendability.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Nystatin Oral Suspension, USP, 500,000 units/5 mL, For Institutional Use Only, packaged in 5 mL cups, Rx Only, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-4810-05

Affected NDC 0121-4810-05

Compare with the code on your package — it is the most precise check available.

Drug: Nystatin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Nystatin
NDC 00121-4810
100000 [USP'U]/mL Suspension
Oral
Pharmaceutical Associates, Inc. Rx
Recalling firm
Pharmaceutical Associates Inc
NDC code
0121-4810-05
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0865-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nystatin recalls

See all
Class II · Moderate risk

Nystatin Cream USP

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Ongoing Wrong potency / content Padagis US LLC NDC 45802-059-35 D-0677-2026
Class II · Moderate risk

Nystatin 150 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk

Nystatin 2 Bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk

Nystatin 500 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-3 D-0155-2024

Other recalls by Pharmaceutical Associates Inc

All 2018 recalls
Class II · Moderate risk

Cyproheptadine HCl Syrup

Failed Impurities/Degradation Specifications : Out-of-specification result for an unidentified impurity at the 12 month stability test point.

Terminated Impurity / degradation Pharmaceutical Associates Inc NDC 0121-4788-10 D-0240-2015